Biocon Boosts Control, Lifts Stake in Biocon Biologics to ~98% via $200M Share Buyout

has strengthened its ownership in its biosimilars arm, Biocon Biologics, raising its stake to approximately 98% after completing a $200 million share buyout of remaining minority holdings, marking a strategic step toward full consolidation and tighter operational integration; this follows prior capital actions including a ₹4,150 crore (~$460 million) Qualified Institutions Placement (QIP) to fund acquisitions and debt repayment as part of its broader plan to make Biocon Biologics a near-wholly owned subsidiary, enhance global execution capability, and simplify the group’s structure as it competes across key markets and therapeutic areas. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.